Masimo prevails in patent infringement case
This article was originally published in The Gray Sheet
California federal appeals court denies Tyco/Nellcor's appeals and places a permanent injunction on the affected Nellcor pulse oximetry products, according to Masimo. In March 2004, a Los Angeles federal court jury found that Nellcor had infringed Masimo's patents and subsequently awarded Masimo $134.5 mil. According to Masimo, that figure was increased to $164 mil. when Nellcor continued to infringe on its products through May 2004. Masimo claims that damages have accrued further since the final judgment. Nellcor is the pulse oximetry market leader, with Masimo holding a distant second place spot (1"The Gray Sheet" April 5, 2004, p. 26)...
You may also be interested in...
Tyco unit Nellcor could face treble damages and an injunction against sales following a recent jury finding of willful infringement of four Masimo pulse oximetry patents, according to Masimo
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.